Physician profile
David B Lalezari
NPI 1093094427
$3,990.76
in general payments reported to CMS, 2019-2025
32 companies · $570 in 2025
The $570 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $486 · 2021: $747 · 2022: $598 · 2023: $632 · 2024: $526 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $549.84 | 2020-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $466.67 | 2022-2024 | |
| Pfizer INC. | $378.66 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.52 | 2021-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $307.24 | 2019-2024 | Spravato |
| Lilly USA, LLC | $278.40 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $232.82 | 2019-2021 | |
| Astellas Pharma US INC | $189.29 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $162.52 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $130.03 | 2019 | |
| Sumitomo Pharma America, INC. | $126.67 | 2025 | Gemtesa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $115.60 | 2025 | Lifevest |
| Cardiovascular Systems INC. | $111.11 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $106.50 | 2023-2025 | Breztri |
| Novo Nordisk INC | $81.44 | 2021-2025 | Wegovy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $42.21 | 2020 | |
| Intuitive Surgical, INC. | $37.53 | 2020 | |
| Eisai INC. | $36.41 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $35.54 | 2021 | |
| Merck Sharp & Dohme LLC | $32.31 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $31.22 | 2025 | Ultomiris |
| Melinta Therapeutics, LLC | $29.29 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.09 | 2024 | |
| Ironwood Pharmaceuticals, INC | $23.72 | 2020 | |
| Ani Pharmaceuticals, INC. | $23.67 | 2025 | Purified Cortrophin Gel |
| Esperion Therapeutics, INC. | $23.25 | 2024 | Nexletol |
| Braeburn INC. | $19.73 | 2024 | Brixadi |
| Azurity Pharmaceuticals, INC. | $19.61 | 2024 | |
| Itamar Medical INC | $15.98 | 2023 | Watchpatone |
| Bayer Healthcare Pharmaceuticals INC. | $15.59 | 2025 | |
| Exact Sciences Corporation | $14.41 | 2025 | Cologuard Collection Kit |
| Orexo US, INC. | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lalezari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.